Result

Univariate Analysis

Characteristic N = 2001
Chemotherapy Treatment
    Drug A 98 (49%)
    Drug B 102 (51%)
Age 47 (38, 57)
    Unknown 11
Marker Level (ng/mL) 0.64 (0.22, 1.41)
    Unknown 10
T Stage
    T1 53 (27%)
    T2 54 (27%)
    T3 43 (22%)
    T4 50 (25%)
Grade
    I 68 (34%)
    II 68 (34%)
    III 64 (32%)
Tumor Response 61 (32%)
    Unknown 7
Patient Died 112 (56%)
Months to Death/Censor 22.4 (15.9, 24.0)
1 n (%); Median (Q1, Q3)

The study included 200 patients receiving chemotherapy, of whom 98 (49%) received Drug A and 102 (51%) received Drug B. The median age of the patients was 47 years (IQR: 38–57), with age information unavailable for 11 patients. The median marker level was 0.64 ng/mL (IQR: 0.22–1.41), with 10 patients having missing values. Regarding tumor stage, 53 patients (27%) had T1 disease, 54 (27%) had T2, 43 (22%) had T3, and 50 (25%) had T4 disease. Tumor grade was similarly distributed, with 68 patients (34%) having Grade I, 68 (34%) Grade II, and 64 (32%) Grade III tumors. Tumor response was reported for 61 patients (32%), while response status was unknown for 7 patients. During follow-up, 112 patients (56%) died, while the remaining 88 (44%) were censored. The median time to death or censoring was 22.4 months (IQR: 15.9–24.0).

trial %>%
  select(
    trt, age, stage, ttdeath
  ) %>% 
  tbl_summary()
Characteristic N = 2001
Chemotherapy Treatment
    Drug A 98 (49%)
    Drug B 102 (51%)
Age 47 (38, 57)
    Unknown 11
T Stage
    T1 53 (27%)
    T2 54 (27%)
    T3 43 (22%)
    T4 50 (25%)
Months to Death/Censor 22.4 (15.9, 24.0)
1 n (%); Median (Q1, Q3) 
trial %>%
  select(
    trt, age, stage, ttdeath
  ) %>% 
  tbl_summary(
    statistic = list(
      all_continuous()~c("{mean} ({sd})")
    )
  )
Characteristic N = 2001
Chemotherapy Treatment
    Drug A 98 (49%)
    Drug B 102 (51%)
Age 47 (14)
    Unknown 11
T Stage
    T1 53 (27%)
    T2 54 (27%)
    T3 43 (22%)
    T4 50 (25%)
Months to Death/Censor 19.6 (5.3)
1 n (%); Mean (SD)

Cross Table

trial %>%
  tbl_summary( 
    by=trt,
    statistic = list(
      all_continuous()~c("{mean} ({sd})")
    )
  )
Characteristic Drug A
N = 981		 Drug B
N = 1021
Age 47 (15) 47 (14)
    Unknown 7 4
Marker Level (ng/mL) 1.02 (0.89) 0.82 (0.83)
    Unknown 6 4
T Stage

    T1 28 (29%) 25 (25%)
    T2 25 (26%) 29 (28%)
    T3 22 (22%) 21 (21%)
    T4 23 (23%) 27 (26%)
Grade

    I 35 (36%) 33 (32%)
    II 32 (33%) 36 (35%)
    III 31 (32%) 33 (32%)
Tumor Response 28 (29%) 33 (34%)
    Unknown 3 4
Patient Died 52 (53%) 60 (59%)
Months to Death/Censor 20.2 (5.0) 19.0 (5.5)
1 Mean (SD); n (%)

Among the 200 patients, 98 (49%) received Drug A and 102 (51%) received Drug B. The mean age was similar between the two treatment groups, at 47 (SD 15) years for Drug A and 47 (SD 14) years for Drug B. The mean marker level was 1.02 (SD 0.89) ng/mL in the Drug A group and 0.82 (SD 0.83) ng/mL in the Drug B group. The distribution of T stage was broadly comparable between groups, with T1, T2, T3, and T4 accounting for 29%, 26%, 22%, and 23% of patients receiving Drug A, respectively, compared with 25%, 28%, 21%, and 26% among those receiving Drug B. Similarly, tumor grade was distributed relatively evenly between the groups, with Grade I, II, and III tumors comprising 36%, 33%, and 32% of the Drug A group and 32%, 35%, and 32% of the Drug B group, respectively. Tumor response was observed in 28 (29%) patients receiving Drug A and 33 (34%) receiving Drug B. During follow-up, 52 (53%) patients in the Drug A group and 60 (59%) in the Drug B group died. The mean time to death or censoring was 20.2 (SD 5.0) months for Drug A and 19.0 (SD 5.5) months for Drug B. Overall, the baseline characteristics appeared broadly similar between the two treatment groups, although the marker level and observed tumor response showed some numerical differences.